文献速递生殖医学

地屈孕酮作为孕激素预处理卵巢刺激方案组成部分的新应用:一项纳入516个首次IVF/ICSI周期的随机对照试验

New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
PubMed 文献 · Hum Reprod · 2018-01-01

这项前瞻性随机对照试验纳入516例36岁以下、卵巢储备正常、因输卵管因素不孕首次行IVF/ICSI的患者,1:1随机分为hMG+地屈孕酮组(260例)和hMG+醋酸甲羟孕酮组(256例),采用全胚冷冻策略。两组获卵数、获卵率、每获卵活胚率及首次冻胚移植临床妊娠率均无显著差异,地屈孕酮组平均LH水平始终高于醋酸甲羟孕酮组(P<0.001),但两组均无患者发生早发LH峰。

要点

  • 地屈孕酮可作为孕激素预处理卵巢刺激方案中合适的替代孕激素。
  • 两组获卵数、获卵率、每获卵活胚率及首次冻胚移植临床妊娠率均无显著差异。
  • 地屈孕酮组平均LH水平始终高于醋酸甲羟孕酮组(P<0.001),但两组均无早发LH峰。

核心结论

  • 地屈孕酮可作为孕激素预处理卵巢刺激方案中合适的替代孕激素。
  • 地屈孕酮在常规剂量下对排卵无抑制或仅弱抑制,可作为hMG佐剂用于卵巢刺激,提示其作为IVF中孕激素预处理卵巢刺激方案合适替代孕激素的新应用可能。

研究设计与样本

  • 前瞻性随机对照试验,2015年11月至2016年11月纳入516例患者,计算机随机按1:1分为hMG+地屈孕酮组(260例)和hMG+醋酸甲羟孕酮组(256例),行IVF或ICSI并采用全胚冷冻策略,每例仅纳入一个周期。
  • 纳入标准为年龄小于36岁、卵巢储备正常、因输卵管因素不孕首次行IVF/ICSI的患者。
  • 主要结局为获卵数,样本量按90%把握度检测2个卵母细胞的差异设定。
  • 两种孕激素均在月经周期第3天开始同步给药,用GnRH激动剂联合hCG触发卵母细胞成熟,所有可移植胚胎冷冻保存,仅纳入第一次冻胚移植周期。

主要发现

  • 两组年龄、BMI及不孕年限等基本特征可比。
  • 获卵数(均值±标准差):hMG+地屈孕酮组10.8±6.3 vs hMG+醋酸甲羟孕酮组11.1±5.8,P=0.33,无显著差异。
  • 获卵率:hMG+地屈孕酮组74.3±19.6% vs hMG+醋酸甲羟孕酮组75.0±19.5%,P=0.69,无显著差异。
  • 每获卵活胚率:hMG+地屈孕酮组37.4%(1052/2815) vs hMG+醋酸甲羟孕酮组35.6%(1009/2837),OR 1.08,95%CI 0.97-1.21,P=0.16,无显著差异。
  • 整个卵巢刺激过程中,hMG+地屈孕酮组平均LH水平始终高于hMG+醋酸甲羟孕酮组(P<0.001);两组均无患者发生早发LH峰,也无患者发生中重度卵巢过度刺激综合征。

局限性

  • 患者和医生对研究分组未设盲。
  • 临床试验结束时大部分患者仍处于妊娠状态,因此随访期间未观察到活产率。
  • 试验设计未涉及地屈孕酮给药的剂量效应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can dydrogesterone (DYG) be used as an alternative progestin in a progesterone primed ovarian stimulation (PPOS) protocol? SUMMARY ANSWER: DYG can be used as an appropriate alternative progestin in a PPOS protocol. WHAT IS KNOWN ALREADY: PPOS is a new ovarian stimulation regimen based on a freeze-all strategy that uses progestin as an alternative to a GnRH analog for suppressing a premature LH surge during the follicular phase. Medroxyprogesterone acetate (MPA) has been successfully used as an adjuvant to gonadotrophin in the PPOS protocol. However, the use of MPA may lead to stronger pituitary suppression and thus may require a higher dosage of hMG and a longer duration of ovarian stimulation than that of conventional ovarian stimulation protocol. STUDY DESIGN SIZE, DURATION: A prospective RCT including 516 patients was performed between November 2015 and November 2016. Computerized randomization was conducted to assign participants at a 1:1 ratio into two treatment groups: an hMG + DYG group (260 patients) or an hMG + MPA group (256 patients) followed by IVF or ICSI with the freeze-all strategy. One cycle per patient was included. The primary outcome of the trial was the number of oocytes retrieved. The sample size was chosen to detect a difference of two oocytes with a power of 90%. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients under 36 years of age with normal ovarian reserve who were undergoing their first IVF/ICSI procedure due to tubal factor infertility were randomized into two groups based on the oral progestin protocol used: hMG co-treatment with DYG (hMG + DYG) or hMG co-treatment with MPA (hMG + MPA). The different progestin was simultaneously administered at the beginning of menstrual cycle 3 (MC3). Oocyte maturation was co-triggered by administration of a GnRH agonist and hCG. All viable embryos from both protocols were cryopreserved for later transfer. Only the first frozen embryo transfer (FET) cycle was included in our study. The embryological and clinical outcomes were measured. MAIN RESULTS AND THE ROLE OF CHANCE: Basic characteristics, such as age, BMI and infertility duration, in both groups were comparable. There was no significant difference in the number (mean ± SD) of oocytes retrieved [10.8 ± 6.3 for the hMG + DYG group versus 11.1 ± 5.8 for the hMG + MPA group, P = 0.33] or the oocyte retrieval rate [74.3 ± 19.6% for the hMG + DYG group versus 75.0 ± 19.5% for the hMG + MPA group, P = 0.69] between the groups. The viable embryo rate per oocyte retrieved did not differ between the two groups [odds ratio (OR): 1.08, 95% CI: 0.97-1.21, P = 0.16]: 37.4% (1052/2815) for the hMG + DYG group versus 35.6% (1009/2837) for the hMG + MPA group. During the whole process of ovarian stimulation, the mean LH level in the hMG + DYG group was always higher than that in the hMG + MPA group (P < 0.001); however, no patient from either group experienced a premature LH surge. In addition, no patients experienced moderate or severe ovarian hyperstimulation syndrome during the ovarian stimulation. No significant difference was found in the clinical pregnancy rate of the first FET cycle between the two groups (OR: 0.82, 95% CI: 0.56-1.21, P = 0.33): 57.6% for the hMG + DYG group (125/217) versus 62.3% for the hMG + MPA group (132/212). LIMITATIONS REASONS FOR CAUTION: The patients and physician were not blinded to the study. Further, a large proportion of patients were still pregnant at the end of the clinical trial, therefore live birth rates were not observed in the follow-up period. The dose-effectiveness of DYG administration was not addressed in the trial design. WIDER IMPLICATIONS OF THE FINDINGS: DYG, which exhibits no or only weak inhibition of ovulation in normal dosage, can serve as an hMG adjuvant during ovarian stimulation. This finding suggests the possibility of a new application of DYG: as an appropriate alternative progestin for a PPOS protocol in IVF. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by The National Nature Science Foundation of China (Grant no. 81503603), Shanghai Three-year Plan on Promoting TCM Development (Grant no. ZY3-LCPT-2-2006) and the Natural Science Foundation of Shanghai (Grant nos. 15401932700 and 15ZR1424900). None of the authors declare any conflict of interest. TRIAL REGISTRATION NUMBER: Chictr.org.cn: ChiCTR-IPR-15007251. TRIAL REGISTRATION DATE: Chictr.org.cn: 22 October 2015. DATE OF FIRST PATIENT’S ENROLLMENT: 1 November 2015.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018. PMID: 29300975. doi:10.1093/humrep/dex367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。